產(chǎn)品[
TIB-18 P3/NSI/1-Ag4-1[NS-1] 小鼠骨髓瘤細胞
]資料
如果您對該產(chǎn)品感興趣的話(huà),可以
產(chǎn)品名稱(chēng):
TIB-18 P3/NSI/1-Ag4-1[NS-1] 小鼠骨髓瘤細胞
產(chǎn)品型號:
TIB-18
產(chǎn)品廠(chǎng)商:
美國標準生物品收藏中心（ATCC）
產(chǎn)品文檔:
無(wú)相關(guān)文檔
簡(jiǎn)單介紹
TIB-18 P3/NSI/1-Ag4-1[NS-1] 小鼠骨髓瘤細胞，原代細胞|細胞系|細胞株|菌種；細胞庫管理規范，提供的細胞株背景清楚，提供參考文獻和Z優(yōu)培養條件！
TIB-18 P3/NSI/1-Ag4-1[NS-1] 小鼠骨髓瘤細胞
的詳細介紹
TIB-18 P3/NSI/1-Ag4-1[NS-1] 小鼠骨髓瘤細胞
|
|
TIB-18?
|
|
$355.00
|
|
|
P3/NSI/1-Ag4-1 [NS-1]
|
|
|
G Kohler, C Milstein
|
|
|
kappa light chain
|
|
Biosafety Level:
|
1
|
|
|
frozen
|
|
|
See Propagation
|
|
|
suspension
|
|
|
Mus musculus (mouse)
|
|
|
lymphoblast
![TIB-18 P3/NSI/1-Ag4-1[NS-1] 小鼠骨髓瘤細胞](http://www.atcc.org/images/icon.jpg)
|
|
|
Disease: plasmacytoma; myeloma
Strain: BALB/c
Cell Type: B lymphocyte;
|
|
|
immunoglobulin (not secreted)
|
|
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
|
|
|
H-2d
|
|
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
|
|
|
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10(5) viable cells/ml. Maintain cell density between 1 X 10(5) and 1 X 10(6) viable cells/ml. Do not allow the cell density to exceed 1 X 10(6) cells/ml.
Medium Renewal: Every 2 to 3 days
|
|
|
Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liqid nitrogen vapor phase
|
|
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002
recommended serum:ATCC 30-2020
parental cell line:ATCC TIB-9
|
|
|
956: Barnstable CJ, et al. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens -- new tools for genetic analysis. Cell 14: 9-20, 1978. PubMed: 667938
1115: Kohler G, et al. Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur. J. Immunol. 6: 292-295, 1976. PubMed: 825374
22154: Horibata K, Harris AW. Mouse myelomas and lymphomas in culture. Exp. Cell Res. 60: 61-77, 1970. PubMed: 5439579
22347: Kohler G, Milstein C. Derivation of specific antibody-producing tissue culture and tumor lines by cell fusion. Eur. J. Immunol. 6: 511-519, 1976. PubMed: 825377
23366: Sato JD, et al. Effects of proximate cholesterol precursors and steroid hormones on mouse myeloma growth in serum-free medium. In Vitro Cell. Dev. Biol. 24: 1223-1228, 1988. PubMed: 3209588
26333: Ramasamy R, et al. Possible role for the Fc receptor on B lymphocytes. Nature 249: 573-574, 1974. PubMed: 4545851
26344: Cowan NJ, et al. Intracellular immunoglobulin chain synthesis in non-secreting variants of a mouse myeloma: detection of inactive light-chain messenger RNA. J. Mol. Biol. 90: 691-701, 1974. PubMed: 4449137
33092: Condie R, et al. Cannabinoid inhibition of adenylate cyclase-mediated signal transduction and interleukin 2 (IL-2) expression in the murine T-cell line, EL4.IL-2. J. Biol. Chem. 271: 13175-13183, 1996. PubMed: 8662742
|
|
